Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixabepilone in DRP-selected metastatic breast cancer
NCT04796324Phase 2Terminated
- Sponsor
- Allarity Therapeutics
- Start
- Mar 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of ixabepilone in breast cancer, sponsored by Allarity Therapeutics. Started Mar 2021; status: terminated.
02
Drugs
ixabepilone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04796324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796324.